Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
Cryptococcus neoformans is an opportunistic fungal pathogen that causes life-threatening infections of the central nervous system. Existing therapies include amphotericin B, fluconazole, and flucytosine, which are limited by toxic side effects and the emergence of drug resistance. We recently demonstrated that the protein phosphatase calcineurin is required for growth at 37 degrees C and virulence of C. neoformans. Because calcineurin is the target of potent inhibitors in widespread clinical use, cyclosporine and FK506 (tacrolimus), it is an attractive drug target for novel antifungal agents. Here we have explored the synergistic potential of combining the calcineurin inhibitor FK506 or its nonimmunosuppressive analog, L-685,818, with other antifungal agents and examined the molecular basis of FK506 action by using genetically engineered fungal strains that lack the FK506 target proteins FKBP12 and calcineurin. We demonstrate that FK506 exhibits marked synergistic activity with the H(+)ATPase inhibitor bafilomycin A(1) via a novel action distinct from calcineurin loss of function. FK506 also exhibits synergistic activity with the pneumocandin MK-0991/caspofungin acetate (formerly L-743,873), which targets the essential beta-1,3 glucan synthase, and in this case, FK506 action is mediated via FKBP12-dependent inhibition of calcineurin. Finally, we demonstrate that FK506 and fluconazole have synergistic activity that is independent of both FKBP12 and calcineurin and may involve the known ability of FK506 to inhibit multidrug resistance pumps, which are known to export azoles from fungal cells. In summary, our studies illustrate the potential for synergistic activity of a variety of different drug combinations and the power of molecular genetics to define the mechanisms of drug action, as well as identify a novel action of FK506 that could have profound implications for therapeutic or toxic effects in other organisms, including humans.
Del Poeta
M
M
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Cruz
M C
MC
Cardenas
M E
ME
Perfect
J R
JR
Heitman
J
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D019703:Calcineurin / Q000378:metabolism; D065095:Calcineurin Inhibitors; D000077336:Caspofungin; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D004338:Drug Combinations; D004357:Drug Synergism; D054714:Echinocandins; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D020104:Immunophilins / Q000378:metabolism; D055666:Lipopeptides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D010455:Peptides; D010456:Peptides, Cyclic; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D022021:Tacrolimus Binding Proteins
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D065095:Calcineurin Inhibitors; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D018942:Macrolides; D010455:Peptides; D010456:Peptides, Cyclic; C057620:bafilomycin A; C076383:L 685818; D015725:Fluconazole; D019703:Calcineurin; D022021:Tacrolimus Binding Proteins; D020104:Immunophilins; D000077336:Caspofungin; D016559:Tacrolimus